GUYER DAVID R 4
4 · EyePoint Pharmaceuticals, Inc. · Filed May 16, 2024
Insider Transaction Report
Form 4
GUYER DAVID R
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-05-14−3,250→ 9,750 totalExercise: $3.50From: 2024-02-23Exp: 2033-06-19→ Common Stock (3,250 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-14−6,525→ 19,575 totalExercise: $3.26From: 2024-01-06Exp: 2033-06-19→ Common Stock (6,525 underlying) - Exercise/Conversion
Common Stock
2024-05-14$3.26/sh+6,525$21,272→ 13,925 total - Exercise/Conversion
Common Stock
2024-05-14$3.50/sh+3,250$11,375→ 17,175 total - Sale
Common Stock
2024-05-14$12.65/sh−11,625$147,045→ 5,550 total
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.44 to $12.83. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.